West Pharmaceutical Services: repays $130,000,000 and enters new credit agreement

What happened

• West Pharmaceutical Services filed an 8-K on Oct 26, 2026, reporting that it used a portion of the proceeds from borrowings under a new credit agreement to prepay and terminate its Credit Agreement dated Mar 28, 2019 (the "Existing Credit Agreement").
• As of the effective date, $130,000,000 in aggregate principal was outstanding under the Existing Credit Agreement and was repaid in full on Oct 26, 2026. The company reported it did not incur any early termination penalties.

Key details

• Effective date of the new credit agreement and repayment: Oct 26, 2026.
• Outstanding repaid under the Existing Credit Agreement: $130,000,000 in aggregate principal.
• The Existing Credit Agreement involved West Pharmaceutical Services, other borrowers party thereto, Bank of America, N.A. as administrative agent, and participating banks and financial institutions.
• The filing reported Items 1.01 (entry into a material definitive agreement), 1.02 (termination of a material definitive agreement) and 2.03 (creation of a direct financial obligation).

Why it may matter

• Item 1.01 covers the company entering into a new credit agreement; Item 1.02 covers termination of the Existing Credit Agreement; Item 2.03 covers the creation of the new direct financial obligation from borrowings under the new credit agreement.
• The filing does not show why the insider traded or why the company acted.